OPKO Health Updates Business Address, Phone, Confirms NASDAQ Listing

TL;DR

**OPKO Health just filed an 8-K updating its contact info and confirming its NASDAQ listing.**

AI Summary

OPKO Health, Inc. filed an 8-K on January 3, 2024, to update its corporate information, specifically its business address to 4400 Biscayne Blvd., Miami, Florida 33137, and its telephone number to (305) 575-4100. This filing also confirms its common stock, with a par value of $0.01 per share, is traded on the NASDAQ Global Select Market under the symbol OPK. This matters to investors as it provides current, accurate contact and trading information, ensuring transparency and ease of communication with the company.

Why It Matters

This filing provides updated contact information and confirms the company's stock exchange listing, which is crucial for investors needing to reach the company or verify trading details.

Risk Assessment

Risk Level: low — This filing is purely administrative, updating contact details and confirming existing trading information, posing no direct financial risk.

Analyst Insight

Investors should update their records with the latest contact information for OPKO Health, Inc. and note the confirmation of its NASDAQ listing, which reinforces its public trading status.

Key Numbers

• $0.01 — Par value per share (The par value of OPKO Health's Common Stock.)

Key Players & Entities

• OPKO Health, Inc. (company) — the registrant filing the 8-K
• NASDAQ Global Select Market (company) — the exchange where OPKO's common stock is registered
• $0.01 (dollar_amount) — par value per share of common stock
• January 3, 2024 (date) — date of earliest event reported
• 4400 Biscayne Blvd. Miami, Florida 33137 (company) — OPKO Health's principal executive offices address
• (305) 575-4100 (company) — OPKO Health's telephone number

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock , par value $0.01 per share OPK NASDAQ Global Select M
• $200.0 — o the launch of its private offering of $200.0 million aggregate principal amount

Filing Documents

• opk20240101_8k.htm (8-K) — 29KB
• ex_611081.htm (EX-99.1) — 15KB
• ex_611065.htm (EX-99.2) — 16KB
• ex_591605img001.jpg (GRAPHIC) — 4KB
• page1.jpg (GRAPHIC) — 101KB
• page2.jpg (GRAPHIC) — 368KB
• page3.jpg (GRAPHIC) — 167KB
• page4.jpg (GRAPHIC) — 257KB
• page5.jpg (GRAPHIC) — 272KB
• page6.jpg (GRAPHIC) — 273KB
• page7.jpg (GRAPHIC) — 258KB
• page8.jpg (GRAPHIC) — 221KB
• page9.jpg (GRAPHIC) — 257KB
• page10.jpg (GRAPHIC) — 257KB
• page11.jpg (GRAPHIC) — 96KB
• page12.jpg (GRAPHIC) — 240KB
• page13.jpg (GRAPHIC) — 245KB
• page14.jpg (GRAPHIC) — 190KB
• page15.jpg (GRAPHIC) — 85KB
• page16.jpg (GRAPHIC) — 180KB
• page17.jpg (GRAPHIC) — 310KB
• page18.jpg (GRAPHIC) — 207KB
• page19.jpg (GRAPHIC) — 272KB
• page20.jpg (GRAPHIC) — 284KB
• page21.jpg (GRAPHIC) — 88KB
• page22.jpg (GRAPHIC) — 232KB
• page23.jpg (GRAPHIC) — 90KB
• page24.jpg (GRAPHIC) — 213KB
• page25.jpg (GRAPHIC) — 85KB
• page26.jpg (GRAPHIC) — 160KB
• 0001437749-24-000456.txt ( ) — 7640KB
• opk-20240103.xsd (EX-101.SCH) — 3KB
• opk-20240103_def.xml (EX-101.DEF) — 11KB
• opk-20240103_lab.xml (EX-101.LAB) — 15KB
• opk-20240103_pre.xml (EX-101.PRE) — 11KB
• opk20240101_8k_htm.xml (XML) — 2KB

01

ITEM 7.01. Regulation FD Disclosure.   On January 3, 2024, OPKO Health, Inc., a Delaware corporation (the "Company"), posted an updated investor presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The presentation is also available on the OPKO website at www.opko.com under "Investors." Information contained on, or accessible through, the Company's website is not a part of and is not incorporated by reference in this Current Report on Form 8-K.   The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, unless expressly stated otherwise.  

01

ITEM 8.01. Other Events.   On January 3, 2024, the Company issued a press release in accordance with Rule 135c promulgated under the Securities Act with respect to the launch of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act.  In accordance with Rule 135c(d), a copy of such press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference in this Item 8.01.  

Financial Statements and Exhibits

Financial Statements and Exhibits.     (d) Exhibits   Exhibit  No.   Description     99.1   Investor Presentation, dated January 3, 2024. 99.2   Rule 135c Press Release of the Company, dated January 3, 2024. 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)        

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       OPKO Health, Inc.             By: /s/ Steven D. Rubin Date: January 3, 2024   Name: Steven D. Rubin     Title: Executive Vice President-Administration            

View Full Filing

View this 8-K filing on SEC EDGAR